Metabolic Diseases Study Group, Division of Endocrinology and Metabolism, Department of Internal Medicine, Universidad del Cauca, Popayán, Cauca, Colombia.
J Diabetes Res. 2018 Feb 12;2018:2052101. doi: 10.1155/2018/2052101. eCollection 2018.
To achieve good metabolic control in diabetes and maintain it in the long term, a combination of changes in lifestyle and pharmacological treatment is necessary. The need for insulin depends upon the balance between insulin secretion and insulin resistance. Insulin is considered the most effective glucose-lowering therapy available and is required by people with type 1 diabetes mellitus to control their blood glucose levels; yet, many people with type 2 diabetes mellitus will also eventually require insulin therapy, due to the progressive nature of the disease. A variety of long-acting insulins is currently used for basal insulin therapy (such as insulin glargine, degludec, and detemir), each having sufficient pharmacodynamic and pharmacokinetic profiles to afford lower intrapatient variability and an extended duration of action. The new glargine-300 formulation was developed to have a flatter and more extended time-action profile than the original glargine-100, and these characteristics may translate into more stable and sustained glycemic control over a 24 h dosing interval. The objective of this comprehensive review was to summarize the available evidence on the clinical efficacy and safety of glargine-300 versus glargine-100 from the EDITION clinical trial program, in patients with type 1 and type 2 diabetes mellitus.
为了在糖尿病中实现良好的代谢控制并长期维持，需要改变生活方式和药物治疗相结合。胰岛素的需求取决于胰岛素分泌和胰岛素抵抗之间的平衡。胰岛素被认为是目前最有效的降血糖治疗方法，1 型糖尿病患者需要用它来控制血糖水平；然而，由于疾病的进展性，许多 2 型糖尿病患者最终也需要胰岛素治疗。目前有多种长效胰岛素用于基础胰岛素治疗（如甘精胰岛素、地特胰岛素和德谷胰岛素），每种胰岛素都具有足够的药效学和药代动力学特征，可降低个体内变异性并延长作用持续时间。新的甘精胰岛素 300 制剂的开发目的是使其时间-作用曲线比原来的甘精胰岛素 100 更平坦、更持久，这些特征可能转化为在 24 小时给药间隔内更稳定和持续的血糖控制。本综述的目的是总结 EDITION 临床试验计划中关于甘精胰岛素 300 与甘精胰岛素 100 在 1 型和 2 型糖尿病患者中的临床疗效和安全性的现有证据。
